Abbott Laboratories Corporation

Jeffrey C Hunt

Joan D Tyner

Xiaoxing Qiu

James W Scheffel

John George Konrath

Sheng C Lou

Tami J Pilot-Matias

John M Robinson

Sushil G Devare

Gregory Thomas Maine

Lawrence V Howard

Susan Brojanac

Michael Jyh-Tsing Sheu

Linda E Chovan

Suresh M Desai

Jack S Remington

James M Casey

Virender K Sarin

Smriti U Mehta

Ilse I Tribby

Stephen F Parmley

Shuli Li

Yashuhiro Suzuki

Fausto Araujo

John G Konrath

Gregory T Maine

Shuili Li

The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.

Monoclonal antibodies to human immunodeficiency virus and uses thereof

Methods for the detection of HIV-1 or -2 antigens employing monoclonal antibodies that recognize a shared HIV-1/-2 epitope in the capsid p24/p26 proteins

Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26)

Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26).

The present invention relates to combinations or mixtures of antigens which may be used in the detection of IgM and/or IgG antibodies to,. Furthermore, the present invention also relates to methods of using these combinations of antigens, antibodies raised against these combinations of antigens or against the novel P29 antigen thereof, as well as kits and vaccines containing the antigens present in the combinations.

Antigen cocktails and uses thereof

The present invention relates to combinations or mixtures of antigens which may be used in the detection of IgM and/or IgG antibodies to,as well as to the P35 antigen which may be used to distinguish acute from chronic toxoplasmosis. Furthermore, the present invention also relates to methods of using these combinations of antigens, antibodies raised against these combinations of antigens or against the novel P29 antigen thereof, as well as kits and vaccines containing the antigens present in the combinations.

Method of using P35 antigen of toxoplasma gondii in distinguishing acute from chronic toxoplasmosis

This invention relates generally to an assay for Lyme disease which detects the antibody to Borrelia burgdorferi, the causative agent of Lyme disease. More specifically, the assay employs antigens derived from amino acid regions in the flagellum of Borrelia burgdorferi. These antigens are immunoreactive with antibodies to Borrelia burgdorferi but are not substantially immunoreactive with antibodies to Treponema pallidum, the syphilis causing agent. DNA sequences of the antigens, clones and vectors containing the DNA sequences are also disclosed. Polypeptides derived therefrom can be used as reagents for the detection of antibody to Borrelia burgdorferi in the body fluids from individuals with Lyme disease.

Borrelia burgdorferi antigens and uses thereof

A mouse monoclonal antibody is provided which detects HIV-2 seropositive individuals and differentiates them from HIV-1 seropositive individuals. The monoclonal antibody is specific for an epitope of HIV-2 gp41 which lies outside the characterized immunodominant region. The epitope recognized by the monoclonal antibody has the amino acid sequence HTTVPW.

Monoclonal antibody for differentiating HIV-2 from HIM-1 seropositive

Growing community of inventors

Mundelein, IL, United States of America

Jeffrey C Hunt